Home

“Compared to other major causes of death in Canada such as cancer and heart attacks […], awareness of COPD remains far too low” (Canadian Lung Association) Last March the CanCold project received its first merits. CanCold saw its protocol published in the prestigious “COPD journal”. 

The “COPD journal” is the first journal dedicated to publishing research on the COPD disease. This gratification demonstrates the effort shown by CanCold’s team to have a better understanding, better management of COPD and to ultimately reduce its impacts.

CanCOLD TEAM

Client Logo
Dr Jean Bourbeau LEAD INVESTIGATOR
Client Logo
Dr Wan Tan CO-PRINCIPAL INVESTIGATOR

CanCOLD TEAM

Dr Jean Bourbeau LEAD INVESTIGATOR
Dr Wan Tan CO-PRINCIPAL INVESTIGATOR

Vision-Mission

CanCOLD (Canadian Cohort of Obstructive Lung Disease) is a prospective multi-center cohort study conducted across Canada, dedicated to increase our understanding on the Chronic Obstructive Pulmonary Disease (COPD) and related co-morbidities, to improve its management and to reduce its burden. This first population based long-term COPD cohort study in Canada is set to end in 2023.

CanCOLD aims to address challenging and important research questions in a more concerted and high-impact fashion by :

Financial Partners

The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is funded by the CIHR (CIHR/ Rx&D Collaborative Research Program Operating Grants- 93326); the Canadian Respiratory Research Network (CRRN); the Respiratory Health Network of the FRSQ; industry partners: Almirall; Astra Zeneca Canada Ltd; Boehringer Ingelheim Canada Ltd; GlaxoSmithKline Canada Ltd; Merck; Novartis; Nycomed; Pfizer Canada Ltd; and Theratechnologies.

The project is led by researchers at RI-MUHC Montreal and Icapture Centre Vancouver.

The Canadian Respiratory Research Network (CRRN) is supported by grants from the Canadian Institutes of Health Research (CIHR) – Institute of Circulatory and Respiratory Health; Canadian Lung Association (CLA)/Canadian Thoracic Society (CTS); British Columbia Lung Association; and Industry Partners Boehringer-Ingelheim Canada Ltd, AstraZeneca Canada Inc., and Novartis Canada Ltd. Funding for training of graduate students and new investigators within the network was supported by the above funding Sponsors and as well by GlaxoSmithKline Inc. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.

PUBLIC FUNDING

INDUSTRY FUNDING